# Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

> **NCT07076212** · PHASE2 · RECRUITING · sponsor: **Medical University of South Carolina** · enrollment: 52 (estimated)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Liposomal Irinotecan
- **DRUG:** Oxaliplatin
- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Gemcitabine (mg/m²)
- **DRUG:** Nab-paclitaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07076212
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-02
- **Primary completion:** 2028-05
- **Final completion:** 2029-11
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07076212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07076212, "Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07076212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*